ERCC1 and biliary tract cancer: Various reports have shown the inverse correlation between high ERCC1 expression levels and clinical CDDP efficacy in patients with ovarian [38], lung [39,40], nasopharyngeal [41], esophageal [42], cervical [43], head and neck [44], and biliary tract cancer [45].